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but also clarify and disseminate infor-
mation on best practices, and ensure that 
the health-care system has the capacity 
to meet the evolving needs of patients 
once they are identifi ed. We must have 
reliable tests that accurately discern at-
risk populations, evidence-based strate-
gies that truly decrease the occurrence of 
adverse outcomes in these patients, and 
the ability to implement these strategies 
eff ectively. Th e fi ndings of Stevens and 
his colleagues5 will help to inform the 
discussion surrounding CKD identifi ca-
tion and management — particularly as 
further data on outcomes from this and 
similar initiatives become available in 
the future.
DISCLAIMER 
The findings and conclusions in this report are 
those of the authors and do not necessarily 
represent the views of the Centers for Disease 
Control and Prevention.
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Tumor necrosis factor-α in 
cisplatin nephrotoxicity: 
A homebred foe?
Z Dong1 and SS Atherton1
A robust inflammatory response involving tumor necrosis factor-α 
(TNF-α) is induced during cisplatin nephrotoxicity. Using chimeric 
models, Reeves and colleagues now demonstrate that resident kidney 
cells, rather than infiltrating immune cells, are the major producers 
of TNF-α. Blockade of TNF-α attenuates inflammation and associated 
kidney injury.
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Cisplatin, a widely used chemothera-
peutic agent, is used to treat a variety of 
cancers. A major drawback of this drug is 
its side eff ects in normal cells and tissues, 
prominently toxicity in the kidneys. Over 
30% of patients develop renal problems 
during cisplatin treatment, which limits 
the use and effi  cacy of cisplatin in can-
cer therapy. Th e cellular and molecular 
mechanism of cisplatin nephrotoxicity 
is a topic of intense investigation, is very 
complex, and involves multiple factors 
and processes, including a robust infl am-
matory response and, ultimately, death of 
renal tubular cells.1
Tumor necrosis factor-α (TNF-α) is a 
key player in the infl ammatory response 
during cisplatin nephrotoxicity. TNF-α 
production was induced under the 
pathological condition.2–4 Importantly, 
in TNF-α-deficient mice, the produc-
tion and secretion of proinfl ammatory 
cytokines and chemokines were attenu-
ated, and this was associated with amel-
ioration of acute kidney injury and renal 
failure during cisplatin treatment. Simi-
lar observations were shown for TNF-α 
inhibition by pharmacological inhibitors 
and neutralizing antibodies.3 Together, 
these studies have demonstrated a critical 
role for TNF-α in mounting the infl am-
matory response during cisplatin neph-
rotoxicity and the ensuing kidney tissue 
damage and acute renal failure.
Given the role of TNF-α in cisplatin 
nephrotoxicity, several important ques-
tions remain. How does cisplatin induce 
TNF-α expression? Where is TNF-α 
produced and by what cells? How does 
TNF-α stimulate the proinfl ammatory 
response? By what mechanism does 
TNF-α induce kidney injury and renal 
failure? Reeves and colleagues5 (this 
issue) have now provided significant 
insights into these important questions. 
Specifi cally, they have demonstrated that 
resident cells of the kidneys, rather than 
infi ltrating infl ammatory cells, are the 
major contributors of TNF-α production 
during cisplatin nephrotoxicity.5
When considering cytokine and chem-
okine production under pathological 
conditions, many of us tend to think 
about an origin from cells of the immune 
system. However, in the kidney, there 
are a variety of cells that can effi  ciently 
produce and secrete cytokines and 
chemokines. For example, production 
of TNF-α has been shown in mesangial 
cells, glomerular cells, endothelial cells, 
and renal tubular cells. So, is TNF-α 
produced by infi ltrating immune cells 
or parenchymal cells of the kidneys? 
To address this question, Reeves and 
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colleagues5 created chimeric models in 
which bone marrow of recipient animals 
was ablated and then reconstituted with 
bone marrow derived from wild-type 
(WT) or TNF knockout (KO) donor 
mice. Th e reconstitution led to four types 
of chimeric mice (donor bone marrow 
genotype → recipient genotype): WT→
WT, KO→WT, WT→KO, and KO→
KO. Aft er cisplatin treatment, the WT 
recipients (WT→WT and KO→WT) 
maintained their capacity for TNF-α 
production, whether WT or TNF-α 
KO bone marrow was reconstituted. 
In sharp contrast, TNF-α production 
was diminished in the TNF-α-defi cient 
recipients, regardless of WT or KO bone 
marrow reconstitution. Th us, cisplatin-
induced TNF-α production in the chi-
meric models was determined by the 
genetic background of the recipient and 
not by the donor bone marrow. Th ese 
are remarkable fi ndings, which suggest 
strongly that TNF-α is produced locally 
by resident cells of the kidneys, rather 
than by bone marrow-derived immune 
cells that infi ltrate the organ during cis-
platin nephrotoxicity. Notably, WT→
WT and KO→WT chimeras developed 
severe kidney injury and renal failure 
aft er cisplatin treatment, whereas WT→
KO and KO→KO chimeras did not. Th is 
observation, although not surprising or 
particularly novel in view of the demon-
strated involvement of TNF-α in cispla-
tin nephrotoxicity, indicates that TNF-α 
produced by the kidneys has an impor-
tant pathogenic role.
In addition to having an elegant experi-
mental design involving chimeric models, 
the study by Reeves and colleagues5 was 
also very carefully controlled. By trans-
plantation of green fl uorescent protein 
(GFP)-labeled bone marrow from GFP 
transgenic mice, they demonstrated a 
high degree of chimerism in the mouse 
models. By two-color fl ow cytometry, they 
showed that bone marrow transplantation 
did not alter the percentage distribution 
of leukocyte subtypes. Th ey further dem-
onstrated that circulating immune cells 
derived from transplanted bone marrow 
retained their ability to produce TNF-α 
upon stimulation by phorbol esters and 
ionomycin, known activators of leuko-
cytes. Th ese are critical controls, which 
indicate that the lack of TNF-α produc-
tion by transplanted immune cells dur-
ing cisplatin nephrotoxicity is not due to 
their faulty behavior, further supporting 
the conclusion that TNF-α is produced 
by resident kidney cells rather than bone 
marrow-derived immune cells.
Although negating a role of bone mar-
row-derived immune cells in TNF-α 
production, the study by Reeves and col-
leagues5 does not exclude the involvement 
of these cells in cisplatin nephrotoxicity. 
Recent work by Rabb and colleagues6 
demonstrated that, as compared with 
wild-type animals, T cell-defi cient mice 
were more resistant to cisplatin nephro-
toxicity. Notably, reconstitution of T cells 
into these animals partially restored their 
sensitivity to cisplatin injury.6 Thus, 
immune cells, particularly the infi ltrating 
T cells, contribute to the development of 
renal pathology during cisplatin treat-
ment. Intriguingly, Rabb and colleagues 
also demonstrated that the production 
of proinfl ammatory cytokines, including 
TNF-α, was attenuated in T cell-defi-
cient mice, suggesting a role for T cells 
in triggering infl ammation and TNF-α 
production during cisplatin nephrotox-
icity.6 Apparently, there is a discrepancy 
between the study by Reeves and col-
leagues and the study by Rabb’s group: 
the former indicates TNF-α production 
by resident kidney cells,5 whereas the 
latter suggests the involvement of infi l-
trating T cells.6 How can these fi ndings 
be reconciled? One possibility is that, 
although TNF-α is produced mainly by 
resident kidney cells, infi ltrating T cells 
may have a regulatory or stimulatory role. 
Th is scenario is supported by the obser-
vation that T-cell infi ltration occurs very 
early (within hours) during cisplatin 
nephrotoxicity.6 Is there indeed a func-
tional interaction between infi ltrating T 
cells and resident kidney cells that leads 
to TNF-α production? How do T cells 
regulate TNF-α production in kidney 
cells? Do they secrete cytokines to prime 
these cells? What specifi c cytokines do 
they produce? Th ese are important ques-
tions for investigation in the future.
Despite the evidence for TNF-α pro-
duction by resident kidney cells, the 
exact identity of the responsible cell 
type(s) has yet to be determined. In the 
kidneys, mesangial cells, glomerular cells, 
endothelial cells, and renal tubular cells 
are all capable of producing TNF-α in 
response to a variety of stimuli. Reeves 
Figure 1 | Schematic diagram depicting TNF-α production and involvement in cisplatin-
induced acute kidney injury. MAPK, mitogen-activated protein kinase; TNFR, TNF-α receptor.
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and colleagues showed recently that cis-
platin treatment induced modest TNF-α 
production in cultured proximal tubular 
cells, which involved gene transcription 
and mRNA stabilization.7 Interestingly, 
in combination with endotoxins, cisplatin 
dramatically increases TNF-α produc-
tion and secretion.8 TNF-α production 
following the combinatorial treatment 
seems to involve an intriguing regulation 
of protein translation via p38 mitogen-
activated protein kinase and the transla-
tion initiation actor eIF4E.8 Th ese novel 
fi ndings suggest that renal tubular cells 
contribute to TNF-α production dur-
ing cisplatin nephrotoxicity and related 
pathological conditions. Certainly, this 
inference needs to be further established 
in vivo, ideally with the use of tubular 
cell-specifi c TNF-α knockout models. 
If it is proven to be true in the kidneys, 
then the same tubular cells are produc-
ing a noxious molecule (TNF-α) to insult 
themselves.
Why is it important to identify the cells 
that produce TNF-α during cisplatin 
nephrotoxicity? First, this is an essential 
step toward a fundamental understanding 
of TNF-α production and infl ammation 
under the pathological condition. Without 
knowing what cells are producing TNF-α, 
it will be very diffi  cult, if not impossible, 
to gain further insights into the underly-
ing molecular mechanisms. Second, many 
cell types are capable of producing TNF-α, 
and the signaling pathways regulating 
TNF-α production in various cells can be 
quite diff erent. As a result, identifi cation 
of the TNF-α-producing cell type(s) may 
focus our eff ort on specifi c pathways in 
these cells for renoprotection during cis-
platin treatment.
How, then, is TNF-α involved in cis-
platin nephrotoxicity? As a pleiotropic 
cytokine, TNF-α induces a variety of 
cellular responses ranging from infl am-
mation to cell death. In a given cell, there 
are two types of TNF-α receptors, TNFR1 
and TNFR2. Binding of the receptors acti-
vates distinct, but not mutually exclusive, 
sig naling cascades. Notably, TNFR1 con-
tains a conserved ‘death domain,’ which, 
upon TNF-α ligation, can trigger the for-
mation of a caspase-activation complex, 
leading to apoptosis. In contrast, TNFR2 
does not have the ‘death domain’ and 
therefore may not be directly involved in 
the initiation of apoptosis. During cispla-
tin-induced nephrotoxicity, renal tubular 
cells undergo both necrotic and apoptotic 
cell death. Several years ago, Tsuruya and 
colleagues showed that proximal tubular 
cells isolated from TNFR1-defi cient mice 
were more resistant to cisplatin-induced 
caspase activation and apoptosis, suggest-
ing the involvement of TNF-α–TNFR1 
signaling in tubular-cell apoptosis under 
the experimental condition.9 On the 
other hand, Reeves and colleagues dem-
onstrated the amelioration of cell death 
in TNFR2-defi cient mice aft er cisplatin 
treatment.10 Importantly, this and sub-
sequent studies indicate that a major 
role of TNF-α is to stimulate the pro-
duction of proinfl ammatory factors and 
recruit infl ammatory cells. Consistent 
with this view, infi ltration of leukocytes 
into the kidneys is reduced in WT→KO 
and KO→KO chimeric mice, suggesting 
that TNF-α produced by resident kidney 
cells is, indeed, critically important in the 
inflammatory response.5 Thus TNF-α 
may trigger tubular-cell death and tis-
sue damage directly via TNFR1 as well as 
indirectly by mounting a robust infl am-
matory response via TNFR2 (Figure 1). 
Nevertheless, while emphasizing the role 
of TNF-α in our discussion, it is impor-
tant to recognize that cisplatin nephro-
toxicity is a multifactorial process. Th us, 
although TNF-α is a significant con-
tributing factor to the pathogenesis, it is 
unlikely to be the only one. Accordingly, 
pharmacological or genetic suppression 
of TNF-α and its signaling aff ords signif-
icant, but not complete, renoprotection 
during cisplatin nephrotoxicity.3,5,9,10 
A fascinating area for future study is to 
decipher how the multiple pathways or 
mechanisms are integrated to orchestrate 
a remarkable renal pathology.
Can we inhibit TNF-α to protect the 
kidneys from cisplatin injury? Th e answer 
is a sound yes, as demonstrated clearly by 
Reeves and colleagues.3,5,10 However, it 
is still not clear whether inhibition of 
TNF-α is an eff ective strategy for reno-
protection during cisplatin-based cancer 
therapy. An ideal approach for reno-
protection during chemotherapy would 
prevent cell injury and death in the kid-
neys, yet preserve cell killing in tumors 
or cancers. Unfortunately, normal tissues 
(including the kidneys) and cancer cells 
share many of the mechanisms of cell 
death in response to cytotoxic insults. 
It is unclear whether TNF-α mediates 
cisplatin-induced cytotoxicity in cancers 
and whether inhibition of TNF-α will 
diminish the chemotherapeutic eff ects 
of cisplatin. Investigation in these areas 
may ultimately lead to the development 
of TNF-α-targeted strategies for renopro-
tection during cisplatin therapy.
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